Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beam Therapeutics (BEAM) Operating Expenses (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Operating Expenses for 7 consecutive years, with $131.6 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 71.93% to $131.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $397.2 million through Dec 2025, down 44.22% year-over-year, with the annual reading at $523.4 million for FY2025, 9.26% up from the prior year.
  • Operating Expenses for Q4 2025 was $131.6 million at Beam Therapeutics, down from $136.5 million in the prior quarter.
  • The five-year high for Operating Expenses was $468.7 million in Q4 2024, with the low at -$324.0 million in Q4 2023.
  • Average Operating Expenses over 5 years is $81.7 million, with a median of $115.6 million recorded in 2021.
  • The sharpest move saw Operating Expenses skyrocketed 606.53% in 2021, then tumbled 323.86% in 2022.
  • Over 5 years, Operating Expenses stood at $114.6 million in 2021, then crashed by 323.86% to -$256.4 million in 2022, then fell by 26.36% to -$324.0 million in 2023, then surged by 244.63% to $468.7 million in 2024, then plummeted by 71.93% to $131.6 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $131.6 million, $136.5 million, and $128.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.